ANAB (AnaptysBio) Float Percentage Of Total Shares Outstanding: 68.14% (As of Jul. 01, 2026)


ANAB AnaptysBio Inc ANAB
66 GF Score
Price $67.50
GF Value $61.32
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AnaptysBio Float Percentage Of Total Shares Outstanding?

AnaptysBio ANAB +2.33% 66 Float Percentage Of Total Shares Outstanding is 68.14% as of Jul. 01, 2026. GuruFocus rates ANAB with a GF Score™ of 66/100 and a GF Value™ of $61.32 (Fairly Valued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AnaptysBio's float shares is 20.18 Mil. AnaptysBio's total shares outstanding is 29.61 Mil. AnaptysBio's float percentage of total shares outstanding is 68.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AnaptysBio's Insider Ownership is 4.21%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AnaptysBio's Institutional Ownership is 102.35%.

ANAB
66GF Score
AnaptysBio Inc ANAB
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnaptysBio Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

AnaptysBio's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=20.18/29.61
=68.14%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 68.14% mean?
AnaptysBio (ANAB) has a Float Percentage Of Total Shares Outstanding of 68.14% as of Jul. 01, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on AnaptysBio and its competitors.
Is AnaptysBio's Float Percentage Of Total Shares Outstanding too high?
AnaptysBio's current Float Percentage Of Total Shares Outstanding is 68.14%. Overall, AnaptysBio has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's Float Percentage Of Total Shares Outstanding compare to ABSI and TSHA?
AnaptysBio's Float Percentage Of Total Shares Outstanding of 68.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on AnaptysBio and its competitors. AnaptysBio's current Float Percentage Of Total Shares Outstanding is 68.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
Based on GuruFocus' analysis, AnaptysBio (ANAB) is currently considered Fairly Valued. The stock's GF Value™ is $61.32, compared to a current price of $67.50 — trading 10.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 68.14%. AnaptysBio's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For AnaptysBio (ANAB), the current Float Percentage Of Total Shares Outstanding is 68.14% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be overvalued. The current stock price of $67.50 is trading 10.1% above its estimated GF Value™ of $61.32. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for ANAB:

  • Float Percentage Of Total Shares Outstanding: 68.14%
  • GF Value™: $61.32 vs. price of $67.50 (10.1% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges 0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
66GF Score

Get the complete analysis for ANAB

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.50
Price
$61.32
GF Value